CR20220317A - Anticuerpos anti-cd73 y usos de estos - Google Patents
Anticuerpos anti-cd73 y usos de estosInfo
- Publication number
- CR20220317A CR20220317A CR20220317A CR20220317A CR20220317A CR 20220317 A CR20220317 A CR 20220317A CR 20220317 A CR20220317 A CR 20220317A CR 20220317 A CR20220317 A CR 20220317A CR 20220317 A CR20220317 A CR 20220317A
- Authority
- CR
- Costa Rica
- Prior art keywords
- antibodies
- disclosed
- vectors
- cells
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Fats And Perfumes (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Se describen anticuerpos anti-CD73. También se describen ácidos núcleicos, vectores, células y composiciones farmacéuticas relacionados. También se describen métodos para tratar el cáncer con los anticuerpos anti-CD73.,
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062956847P | 2020-01-03 | 2020-01-03 | |
PCT/US2020/067533 WO2021138467A1 (en) | 2020-01-03 | 2020-12-30 | Anti-cd73 antibodies and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20220317A true CR20220317A (es) | 2022-09-02 |
Family
ID=74347717
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20220317A CR20220317A (es) | 2020-01-03 | 2020-12-30 | Anticuerpos anti-cd73 y usos de estos |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP4084825A1 (es) |
JP (1) | JP2023509448A (es) |
KR (1) | KR20220121850A (es) |
CN (1) | CN115135341A (es) |
AR (1) | AR120936A1 (es) |
AU (1) | AU2020417804A1 (es) |
BR (1) | BR112022013236A2 (es) |
CA (1) | CA3166533A1 (es) |
CL (1) | CL2022001769A1 (es) |
CO (1) | CO2022009248A2 (es) |
CR (1) | CR20220317A (es) |
EC (1) | ECSP22051701A (es) |
IL (1) | IL294436A (es) |
MX (1) | MX2022007575A (es) |
PE (1) | PE20221409A1 (es) |
TW (1) | TW202128768A (es) |
WO (1) | WO2021138467A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117903140A (zh) | 2018-02-27 | 2024-04-19 | 因赛特公司 | 作为a2a/a2b抑制剂的咪唑并嘧啶和***并嘧啶 |
CA3100731A1 (en) | 2018-05-18 | 2019-11-21 | Incyte Corporation | Fused pyrimidine derivatives as a2a / a2b inhibitors |
TWI829716B (zh) | 2018-07-05 | 2024-01-21 | 美商英塞特公司 | 作為a2a/a2b 抑制劑之稠合吡嗪衍生物 |
TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及***并吡啶 |
MX2023007850A (es) * | 2020-12-29 | 2023-09-11 | Incyte Corp | Terapia combinada que comprende inhibidores de adora2a/adora2b (a2a/a2b), inhibidores de muerte programada/ligando 1 de muerte programada (pd-1/pd-l1) y anticuerpos de cumulo de diferenciacion 73 (anti-cd73). |
CN113025567A (zh) * | 2021-03-31 | 2021-06-25 | 中国人民解放军陆军特色医学中心 | 一种椎间盘单细胞的分离方法 |
WO2023201267A1 (en) | 2022-04-13 | 2023-10-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5156840A (en) | 1982-03-09 | 1992-10-20 | Cytogen Corporation | Amine-containing porphyrin derivatives |
US5057313A (en) | 1986-02-25 | 1991-10-15 | The Center For Molecular Medicine And Immunology | Diagnostic and therapeutic antibody conjugates |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
EP0617706B1 (en) | 1991-11-25 | 2001-10-17 | Enzon, Inc. | Multivalent antigen-binding proteins |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
JP4667383B2 (ja) | 2003-06-13 | 2011-04-13 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | アグリコシル抗cd154(cd40リガンド)抗体およびその使用 |
JP2007503206A (ja) | 2003-08-22 | 2007-02-22 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 変更されたエフェクター機能を有する改良された抗体およびその抗体を産生する方法 |
JP6755866B2 (ja) * | 2014-11-10 | 2020-09-16 | メディミューン リミテッド | Cd73特異的結合分子及びその使用 |
GB2538120A (en) * | 2014-11-11 | 2016-11-09 | Medimmune Ltd | Therapeutic combinations comprising anti-CD73 antibodies and uses thereof |
MX2017006624A (es) * | 2014-11-21 | 2017-08-21 | Bristol Myers Squibb Co | Anticuerpos contra cd73 y sus usos. |
CN109476740A (zh) * | 2016-03-04 | 2019-03-15 | 百时美施贵宝公司 | 利用抗cd73抗体的联合治疗 |
WO2018013611A1 (en) * | 2016-07-11 | 2018-01-18 | Corvus Pharmaceuticals, Inc. | Anti-cd73 antibodies |
MY188386A (en) * | 2017-01-24 | 2021-12-07 | I Mab Biopharma Us Ltd | Anti-cd73 antibodies and uses thereof |
JP7319992B2 (ja) * | 2018-03-09 | 2023-08-02 | アジェナス インコーポレイテッド | 抗cd73抗体およびそれらの使用方法 |
MX2020009366A (es) * | 2018-03-09 | 2020-10-14 | Phanes Therapeutics Inc | Anticuerpos anti-cd73 y usos de los mismos. |
US20210214459A1 (en) * | 2018-05-31 | 2021-07-15 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
-
2020
- 2020-12-30 PE PE2022001337A patent/PE20221409A1/es unknown
- 2020-12-30 AR ARP200103688A patent/AR120936A1/es unknown
- 2020-12-30 CR CR20220317A patent/CR20220317A/es unknown
- 2020-12-30 BR BR112022013236A patent/BR112022013236A2/pt unknown
- 2020-12-30 IL IL294436A patent/IL294436A/en unknown
- 2020-12-30 WO PCT/US2020/067533 patent/WO2021138467A1/en unknown
- 2020-12-30 AU AU2020417804A patent/AU2020417804A1/en active Pending
- 2020-12-30 KR KR1020227025615A patent/KR20220121850A/ko unknown
- 2020-12-30 MX MX2022007575A patent/MX2022007575A/es unknown
- 2020-12-30 CA CA3166533A patent/CA3166533A1/en active Pending
- 2020-12-30 CN CN202080096659.5A patent/CN115135341A/zh active Pending
- 2020-12-30 EP EP20848762.9A patent/EP4084825A1/en active Pending
- 2020-12-30 TW TW109146785A patent/TW202128768A/zh unknown
- 2020-12-30 JP JP2022540938A patent/JP2023509448A/ja active Pending
-
2022
- 2022-06-28 CL CL2022001769A patent/CL2022001769A1/es unknown
- 2022-07-01 CO CONC2022/0009248A patent/CO2022009248A2/es unknown
- 2022-07-01 EC ECSENADI202251701A patent/ECSP22051701A/es unknown
Also Published As
Publication number | Publication date |
---|---|
JP2023509448A (ja) | 2023-03-08 |
AR120936A1 (es) | 2022-03-30 |
CL2022001769A1 (es) | 2023-01-20 |
CO2022009248A2 (es) | 2022-08-19 |
CA3166533A1 (en) | 2021-07-08 |
PE20221409A1 (es) | 2022-09-20 |
AU2020417804A1 (en) | 2022-07-21 |
BR112022013236A2 (pt) | 2022-09-06 |
KR20220121850A (ko) | 2022-09-01 |
MX2022007575A (es) | 2022-09-23 |
TW202128768A (zh) | 2021-08-01 |
CN115135341A (zh) | 2022-09-30 |
IL294436A (en) | 2022-09-01 |
EP4084825A1 (en) | 2022-11-09 |
ECSP22051701A (es) | 2022-08-31 |
US20210230293A1 (en) | 2021-07-29 |
WO2021138467A1 (en) | 2021-07-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20220317A (es) | Anticuerpos anti-cd73 y usos de estos | |
MX2020009514A (es) | Anticuerpos anti-claudina 18.2 (cldn18.2). | |
EP4339287A3 (en) | Modified cells and methods of therapy | |
WO2019006418A3 (en) | ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY | |
PH12020551923A1 (en) | Methods and compositions for treating cancer | |
CR20220396A (es) | Anticuerpos y proteínas de fusión que se unen a ccr8 y usos de estos | |
MX2021002415A (es) | Celulas madre hematopoyeticas modificadas geneticamente y usos de las mismas. | |
MX2020009366A (es) | Anticuerpos anti-cd73 y usos de los mismos. | |
AU2018236742B2 (en) | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same | |
ZA202004730B (en) | Anti-claudin 18.2 antibodies and uses thereof | |
CA3156451A1 (en) | ANTIBODIES WITH SPECIFICITY FOR NECTIN-4 AND THEIR USES | |
MX2021006681A (es) | Anticuerpos anti-claudina y usos de los mismos. | |
MX2018006973A (es) | Anticuerpos anti-cd73 humanizados. | |
PH12020551907A1 (en) | Antagonizing cd73 antibody | |
WO2021007428A3 (en) | Molecules, compositions and methods for treatment of cancer | |
WO2019090148A3 (en) | Compositions and methods related to therapeutic cell systems for tumor growth inhibition | |
MX2020003339A (es) | Arn guía de cpf1 modificado. | |
MX2020006901A (es) | Composiciones de pares de bases no naturales y procedimientos de uso. | |
WO2019056023A3 (en) | Claudin6 antibodies and methods of treating cancer | |
EA202191257A1 (ru) | Противораковая терапия на основе иммуноцитов, связывающих liv1 | |
MX2021012003A (es) | Anticuerpos multiespecificos contra antigeno de cancer de la bomba de eflujo y composiciones, reactivos, kits y metodos relacionados con los mismos. | |
BR112022012867A2 (pt) | Tratamento de câncer com inibidores de cdk12/13 | |
BR112022005114A2 (pt) | Anticorpo, composição farmacêutica, métodos para tratar câncer e para produzir um conjugado anticorpo-fármaco e um anticorpo, ácido nucleico, vetor, célula hospedeira, e, conjugado anticorpo-fármaco | |
WO2022082073A3 (en) | Compositions and methods for muc18 targeting | |
MX2020009522A (es) | Anticuerpos anti-folato del receptor 1 y usos de los mismos. |